share_log

Chardan Capital Maintains Buy on Intellia Therapeutics, Raises Price Target to $91

Benzinga ·  Nov 18 23:23  · Ratings

Chardan Capital analyst Geulah Livshits maintains Intellia Therapeutics (NASDAQ:NTLA) with a Buy and raises the price target from $88 to $91.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment